Clinical aspects of mCRPC management in patients treated with radium-223

Bone is the most common site of metastasis in metastatic castration-resistant prostate cancer (mCRPC), which is associated with pain and skeletal events. Radium-223 dichloride (Xofigo) is an alpha-emitting radioactive isotope that can specifically target bone lesions. Herein, we report the results o...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizzini, Elisa Lodi, Dionisi, Valeria, Ghedini, Pietro, Morganti, Alessio Giuseppe, Fanti, Stefano, Monari, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174360/
https://www.ncbi.nlm.nih.gov/pubmed/32317750
http://dx.doi.org/10.1038/s41598-020-63302-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174360/
https://www.ncbi.nlm.nih.gov/pubmed/32317750
http://dx.doi.org/10.1038/s41598-020-63302-2

Ejemplares similares